Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Changed Course On Zontivity Because Of Skepticism Of Subgroups At High Levels

30 Jul 2014

• By Bridget Silverman

Related Content

<em>Brilinta</em> Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

01 Jan 2012

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

01 Apr 2012

Merck’s Zontivity Label Isn’t Weighed Down With Safety Language

09 May 2014

Related Companies

Merck & Co., Inc.

Additional Topics

Regulation Approvals BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.